In the battle against B-cell cancers, drugs that target the enzyme Bruton tyrosine kinase (BTK) have transformed treatment. Before the first BTK inhibitor, ibrutinib, came on the market in 2013, ...

<Figure 1. Schematic of the diffusion model developed by the research team, which generates molecular structures and non-covalent interactions based on protein structures. Starting from a noise ...